Search Results
Your search for ,wAS matches 28044 pages
Showing 10651 - 10700Recurrence-Free Survival Benefit Maintained With Adjuvant Nivolumab vs Ipilimumab in Stage IIIB–IIIC and IV Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, and colleagues, 4-year results of the CheckMate 238 trial show continued benefit of adjuvant nivolumab vs ipilimumab in recurrence-free survival and metastasis-free...
Breast Cancer and Radiation Researcher David Gius, MD, PhD, Joins Mays Cancer Center
David Gius, MD, PhD, a breast cancer and radiation researcher, has joined the Mays Cancer Center, home to The University of Texas Health San Antonio MD Anderson. He was recruited to the Mays Cancer Center from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University with a $6...
The Secret History of Cancer Chemotherapy
“The summons came in the middle of the night. He was awake at the first harsh jangle of the telephone…. Always a light sleeper, Lieutenant Colonel Stewart Francis Alexander attributed the trait to his father, an old-fashioned family practitioner whose response to every late-night distress call was...
A Gritty Journey Into a Rare Cancer and Back
Over the past decade, a prolific number of cancer memoirs have been published, and some have been award-winning bestsellers. When entering a crowded genre, it is best to have something that sets your story apart. Judith Dwyer Fugate did just that with a memoir about a rare tumor that has rarely if...
Cleveland Clinic Announces Oncology Staff Appointments
Cleveland Clinic recently announced the following additions to its oncology staff: Ruth Keri, PhD, has joined Cleveland Clinic Lerner Research Institute Department of Cancer Biology. She will study breast cancer, focusing on identifying the molecular processes that control the formation of breast...
UCLA Researchers’ Efforts in Melanoma Receive $13M Boost From NIH
University of California, Los Angeles (UCLA) researchers have received a $13 million grant from the National Institutes of Health (NIH) to find new ways to overcome melanoma resistance to some of the most promising targeted therapies and immunotherapies. There have been significant advancements in...
The Gut, Our Choices, and Gynecologic Cancers: Investigating an Unlikely Trio
Disturbance of the gut microbial metabolism is thought to be the root cause of human diseases. Bacteria, viruses, and fungi affect their human hosts in numerous ways. There is evidence to support the theory that microbes, through their genetic makeup, gene products, and metabolites, play a role in...
Expert Point of View: Bartosz Chmielowski, MD, PhD
The invited discussant of LEAP-004, Bartosz Chmielowski, MD, PhD, Associate Clinical Professor at the University of California Los Angeles Jonsson Comprehensive Cancer Center, commented: “The response rate of 21% was quite impressive for this patient population. Patients previously treated with an...
Advanced Melanoma: Lenvatinib Plus Pembrolizumab After Disease Progression on Anti–PD-1 Therapy
Checkpoint inhibitors can be lifesaving for many patients with advanced melanoma, but those who experience disease progression currently have few treatment options. The combination of a tyrosine kinase inhibitor and an anti–PD-1 agent may offer some hope in this setting, according to a study of...
Pay-for-Performance Program to Reimburse Oncology Practices for Prescribing Evidence-Based Cancer Drugs
A pay-for-performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers reported in a study published in the Journal ...
Expert Point of View: Salah-Eddin Al-Batran, MD
Salah-Eddin Al-Batran, MD, Director of the Institute of Clinical Cancer Research and Director of GI Oncology at Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, commented on KEYNOTE-590 at a press briefing. Dr. Al-Batran noted that the prognosis for advanced esophageal cancer is...
First-Line Pembrolizumab Plus Chemotherapy Improves Survival in Esophageal Cancer
As first-line therapy for advanced esophageal cancer, pembrolizumab added to chemotherapy improved overall survival in the KEYNOTE-590 population. Not only did patients with high PD-L1 expression benefit, the value of checkpoint inhibition was observed for the whole population, the trial’s...
Panel With Diverse Perspectives Explores Strategies to Reduce Costs for Cancer Care
“Imagine that it’s 5 years from now, and we are in a situation where the cost of cancer care has flattened, and costs are even going down,” said Clifford Goodman, PhD, a Senior Vice President at the Lewin Group, turning to a panel of oncology and policy experts at his side. “What policies got us...
Isabelle Tabah-Fisch, MD, Drug Researcher, Industry Executive, Dies at 64
Isabelle Tabah-Fisch, MD, a medical oncologist in Paris who contributed greatly to drug development, died August 28, 2020, at age 64. An announcement about Dr. Tabah-Fisch’s death was made by GamaMabs, where she served as Chief Medical Officer until her retirement in March 2020. Under her...
Lesley Solomon, MBA, of Dana-Farber, Receives Extraordinary Women Advancing Healthcare Award
Lesley Solomon, MBA, Senior Vice President for Innovation and Chief Innovation Officer at Dana-Farber Cancer Institute, has received the 2020 Extraordinary Women Advancing Healthcare Award from The Commonwealth Institute, a nonprofit organization devoted to advancing women in leadership positions....
Daughter of an Orthopedic Surgeon, Abigail T. Berman, MD, Finds Radiation Oncology Intriguing
Radiation oncologist Abigail T. Berman, MD, was born and reared in Philadelphia, the daughter of an orthopedic surgeon whose passion for his work was an early influence on her decision to pursue a career in medicine. “My father absolutely adored his job and worked very hard, which inspired me to...
Surgical and Radiation Oncology in Elderly Patients With Cancer
As one might expect, the focus on older patients developed in surgical and radiation oncology at the same time as in medical oncology. As we have done in our overview of medical oncology, we may recognize a prehistory, past history, and present history in surgical and radiation geriatric oncology....
Cancer in Older Adults: The History of Geriatric Oncology, Part 2: 1990–2020
In part 1 of this three-part article, which was published in the October 10, 2020, issue of The ASCO Post, we chronicled the progress made in geriatric oncology up to the decade of the 1990s, which saw an explosion of research activity in the study of aging and cancer. In part 2, we review the...
James K. McCloskey II, MD, Named Division Chief of the Division of Leukemia at John Theurer Cancer Center
James K. McCloskey II, MD, was named Division Chief of the Division of Leukemia at Hackensack Meridian John Theurer Cancer Center (JTCC), part of Hackensack University Medical Center. Dr. McCloskey previously served as Interim Chief for the Division of Leukemia and will continue in his role as...
Expert Point of View: Chiara Cremolini, MD, PhD
The KEYNOTE-177 invited discussant, Chiara Cremolini, MD, PhD, of the University of Pisa, Italy, welcomed the patient-reported outcomes of the study, noting that such data are frequently missing. “Unfortunately, quality of life is an often-disregarded issue in colorectal cancer clinical trials,”...
First-Line Pembrolizumab in Metastatic Colorectal Cancer: Quality of Life Also Improved
In KEYNOTE-177, the anti–PD-L1 antibody pembrolizumab reduced the risk of disease progression by 40% vs chemotherapy in a targeted subset of previously untreated patients with metastatic colorectal cancer. Now, in terms of health-related quality of life, pembrolizumab is also the clear favorite,...
Activity of the KRAS G12C Inhibitor Sotorasib in KRAS G12C–Mutant Advanced Solid Tumors
As reported inThe New England Journal of Medicine by David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, a phase I trial (CodeBreak 100) has shown activity of the oral KRAS G12C inhibitor sotorasib in heavily pretreated patients with KRAS G12C–mutant...
Capmatinib Active in Advanced NSCLC With MET Exon 14 Skipping Mutations
As reported inThe New England Journal of Medicine by Jürgen Wolf, MD, of the Center for Integrated Oncology, University Hospital Cologne and University of Cologne, and colleagues, the phase II GEOMETRY mono-1 trial has shown durable responses with the selective MET inhibitor capmatinib in patients...
Thinking Out of the Box to Advance the Management of Chronic Graft-vs-Host Disease
Over the past decade, the field of allogeneic hematopoietic cell transplantation has made great strides, evolving into a curative procedure for blood cancers that once were almost always fatal. However, chronic graft-vs-host disease, whose biologic etiology remains unclear, continues to be the...
Expert Point of View: Henrik Grönberg, MD
Formal discussant of the -IPATential150 trial, Henrik Grönberg, MD, Professor at Karolinska Institute, Stockholm, found the study results intriguing, especially in the PTEN-loss patients. “Biomarkers are the wave of the future,” he said. “The study population was compared with an adequately...
Ipatasertib/Abiraterone Combination Shows Potential in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
Ipatasertib plus abiraterone plus prednisone achieved significantly superior radiographic progression–free survival and antitumor activity compared with placebo plus abiraterone plus prednisonein patients with metastatic castration-resistant prostate cancer and PTEN loss, according to the results...
Florida Surgeon Steven D. Wexner, MD, FACS, Elected Vice-Chair of Board of Regents of American College of Surgeons
Steven D. Wexner, MD, PhD (Hon), FACS, FRCS (Eng), FRCS (Ed), FRCSI (Hon), Hon FRCS (Glasg), was recently elected Vice-Chair of the Board of Regents of the American College of Surgeons (ACS) during the College’s virtual Clinical Congress 2020, held October 3–7. Dr. Wexner is Chair of the...
Expert Point of View: Henrik Grönberg, MD
Formal discussant of the PROfound trial, Henrik Grönberg, MD, of the Karolinska Institute, Stockholm, agreed that this was a practice-changing trial for select patients. “The patient population is representative, but the problem is the control group, which included patients who experienced disease ...
Olaparib Improves Outcomes in Metastatic Castration-Resistant Prostate Cancer With BRCA1/2 Alterations
The PARP inhibitor olaparib reduced the risk of death by 31% compared with a second hormonal treatment (enzalutamide or abiraterone) in men with metastatic castration-resistant prostate cancer characterized by BRCA1, BRCA2, or ATM mutations, in the final analysis of the phase III PROfound trial...
Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, Honored With Nobel Prize in Chemistry 2020
On October 7, 2020, The Royal Swedish Academy of Sciences announced that the Nobel Prize in Chemistry 2020 would be awarded to Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, “for the development of a method for genome editing,” the CRISPR/Cas9 genetic scissors. “There is enormous power...
2020 Nobel Prize in Physiology or Medicine Awarded to Team Who Discovered Hepatitis C Virus
This year’s Nobel Prize in Physiology or Medicine was awarded to three scientists who have made a decisive contribution to the treatment of blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world. Harvey J. Alter, MD; Michael Houghton,...
Early-Phase Study Reports Progress in Targeting KRAS-Mutated Tumors With Sotorasib
Although KRAS is one of the most frequently mutated oncogenes in human cancers, an almost 4-decade long search for drugs that hit this target has been elusive—until now. Sotorasib (formerly called AMG-510), a small-molecule inhibitor of the KRAS G12C mutation, demonstrated clinical activity and...
Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO
Invited discussant of the EMPOWER-Lung 1 trial, Roy S. Herbst, MD, PhD, FACP, FASCO, Chief, Medical Oncology, Yale Cancer Center, New Haven, Connecticut, pointed out the tremendous progress that has been made since 2000 in treating NSCLC. “In 2000, median survival for advanced NSCLC was 7.9...
EMPOWER-Lung 1 Trial: Cemiplimab Improves Survival Over Chemotherapy in Advanced NSCLC
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 presented several abstracts with good news for patients with lung cancer. Long-term follow-up of immunotherapies showed excellent survival, a promising new ALK inhibitor improved outcomes compared with the standard of care, the...
Co-Leader of Immunotherapy Trial Reflects on ‘Practice-Changing’ Results in Advanced Bladder and Other Urinary Tract Cancers
In a large, randomized clinical trial, researchers evaluated the immunotherapy drug avelumab for patients with advanced urothelial cancer. The findings of the trial, called the JAVELIN Bladder 100 study, are “very exciting,” even “practice-changing,” said the trial’s co-leader, Petros Grivas, MD,...
Novel IAP Blocker Plus Chemoradiotherapy Improved Outcomes in Head and Neck Cancer Trial
Xevinapant, an investigational inhibitor of apoptosis proteins (IAP) blocker, prolonged overall survival when added to standard chemoradiotherapy for locally advanced head and neck squamous cell carcinoma, according to an updated analysis of a randomized, placebo-controlled phase II study presented ...
Expert Point of View: Fatima Cardoso, MD
The encouraging results of the phase III ASCENT trial suggest that sacituzumab govitecan has clearly earned a place in the treatment algorithm for advanced triple-negative breast cancer, said the study’s invited discussant, Fatima Cardoso, MD, Director of the Breast Unit at the Champalimaud...
Sacituzumab Govitecan Yields Survival Benefit as Third-Line Treatment in Triple-Negative Breast Cancer: ASCENT Trial
Based on results from a phase I/II clinical trial, the antibody drug conjugate sacituzumab govitecan was recently granted accelerated approval in the treatment of patients with advanced triple-negative breast cancer, contingent on a larger study confirming its benefit. The confirmatory phase III...
Should Body Mass Index Guide the Choice of Chemotherapy in Patients With Breast Cancer?
The rate of obesity is rising dramatically in the United States and Europe, with more than 60% of women in the United States1,2 and 50% of women in Europe3 classified as overweight or obese based on their body mass index (BMI). Obesity is associated with an increased risk of hormone...
Expert Point of View: Christine M. Lovly, MD, PhD
Lorlatinib was strategically designed to have activity against ALK and to be highly CNS-penetrant,” said formal discussant Christine M. Lovly, MD, PhD, of Vanderbilt Ingram Cancer Center, Nashville. “We look forward to seeing more data from this trial. Alectinib had a progression-free survival of...
Lorlatinib Improves Outcomes Over Crizotinib in First-Line Setting of ALK-Positive NSCLC: CROWN Trial
Lorlatinib significantly improved progression-free survival compared with crizotinib in the first-line treatment of patients with advanced ALK-positive non–small cell lung cancer (NSCLC), according to a planned interim analysis of the phase III CROWN trial presented at the European Society for...
FDA Pipeline: Priority Reviews in EGFR-Mutant Lung Cancer, Advanced Renal Cell Carcinoma; Fast Track Designations in CLL and Solid Tumors
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for EGFR-mutant lung cancer and advanced renal cell carcinoma; granted Fast Track designation to agents in chronic lymphocytic leukemia (CLL) and locally advanced or metastatic solid tumors; and more....
Small Case Study Explores Novel Approach to Neoadjuvant Therapy for Skin Cancer
Skin cancers are the most common malignancy in the United States and worldwide. Between 1994 and 2014, the diagnosis and treatment of melanoma and nonmelanoma skin cancers in the United States increased by 77%.1 The cost of treating melanoma and nonmelanoma skin cancers to the health-care system...
Surufatinib in Advanced Pancreatic Neuroendocrine Tumors
As reported in The Lancet Oncology by Xu et al, the Chinese phase III SANET-p trial has shown significantly improved progression-free survival with surufatinib vs placebo in patients with advanced pancreatic neuroendocrine tumors. Surufatinib is a novel small-molecule inhibitor that targets...
Association of Minimal Residual Disease With Disease-Free and Overall Survival in Patients With AML
In a systematic review and meta-analysis reported in JAMA Oncology, Nicholas J. Short, MD, and colleagues found that minimal (or measurable) residual disease (MRD) negativity is associated with superior disease-free and overall survival in patients with acute myeloid leukemia (AML). As stated by...
Adjuvant vs Salvage Radiotherapy Plus Short-Term ADT After Radical Prostatectomy for Localized Prostate Cancer
As reported in The Lancet Oncology by Sargos et al, the French phase III GETUG-AFU 17 trial has shown no event-free survival benefit for adjuvant radiotherapy vs salvage radiotherapy—both with short-term androgen-deprivation therapy (ADT)—after radical prostatectomy in men with localized prostate...
FDA Approves Remdesivir for Patients With COVID-19 Requiring Hospitalization
On October 22, the U.S. Food and Drug Administration (FDA) approved the antiviral drug remdesivir (Veklury) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kg for the treatment of COVID-19 requiring hospitalization. Remdesivir should only be administered...
Radiation-Induced Genetic Deletions May Be Associated With Poorer Patient Outcomes
Treatment of diffuse gliomas with radiotherapy resulted in an increased number of genomic small deletions that make up a unique signature, according to findings presented at the Molecular Analysis for Precision Oncology (MAP) Congress 2020 (Abstract 2MO). Furthermore, an increased burden of...
Do Patients With Early-Stage NSCLC Have a Higher Tumor Mutational Burden Than Those With More Advanced Disease?
The tumors of patients with stage I and II non–small cell lung cancer (NSCLC) demonstrated a generally higher tumor mutational burden and more often displayed the mutational signature associated with tobacco smoking than those of patients with more advanced disease, according to findings presented...
Addition of Bevacizumab to Paclitaxel in Relapsed Ovarian Sex Cord–Stromal Tumors
In the phase II ALIENOR trial reported in JAMA Oncology, Isabelle Ray-Coquard, MD, and colleagues found that the addition of bevacizumab to paclitaxel did not improve the 6-month progression-free rate among women with relapsed ovarian sex cord–stromal tumors. Study Details The study, performed in...
